TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03474523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Cavitation: 70% intensity, 30 minutes apply plane electrode and 10 minutes focal electrode.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Diathermy-Radiofrecuency: 30 minutes at 70% intensity (40-43ºC) in manual resistive modality and 10 minutes in automatic capacitive modality.~Presotherapy: 30 minutes application of 35% intensity, compression 35seg, pause 15seg, speed 9
Study: NCT01391091

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: PVAI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency catheter ablation
Description: PVAI
Study: NCT02847624

Intervention type: DRUG
Intervention: tolvaptan
Study: NCT00874549

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL. Intramuscular
Study: NCT02653755

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosigna
Description: Transcriptional profile of 50 genes used for risk stratification.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosigna
Description: Transcriptional profile of 50 genes used for risk stratification.
Study: NCT02601365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim 0.04 mcg/kg/dose
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.04 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim 0.2mcg/kg/dose
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 0.2 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim 1 mcg/kg/dose
Description: The final dilution of sargramostim will occur at the bedside by a study team member. Cohort 1 will receive sargramostim 1 mcg/kg/dose nebulized to the inspiratory loop of the patients' mechanical ventilator circuit for 15 minutes.
Study: NCT00966446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unsupervised Decolonization
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supervised Decolonization
Description: Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure compliance, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
Study: NCT01093573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Given orally
Study: NCT00285467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxercalciferol
Description: form of vitamin D that is already in active form.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: from of vitamin D that requires cells in the body to make active
Study: NCT00874549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menactra®: Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT04409054

Intervention type: OTHER
Intervention: Cough and Valsalva effort
Description: Three increasingly cough effort and three Valsalva type effort at four different volumes of rectal distension (empty rectum, volume for a first sensation of filling, volume for desire to defecate and maximal tolerable volume) while recording the external anal sphincter activity
Study: NCT03792139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally.
Study: NCT02482909

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Description: Anatomical surgical resection of the liver including the tumor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: Percutaneous ablation using radiofrequency under the imaging guidance
Study: NCT03792139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3200882
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Administered orally.
Study: NCT00844350

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: letrozole , oxytocin,hCG,clomiphene citrate

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: letrozole , oxytocin,hCG,clomiphene citrate

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: letrozole , oxytocin,hCG,clomiphene citrate

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: letrozole , oxytocin,hCG,clomiphene citrate

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: letrozole , oxytocin,hCG,clomiphene citrate
Study: NCT03045016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin, ALPRESS® LP 2,5 et 5 mg
Description: Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):~* PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days~* PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days.
Study: NCT00662896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 375 mg bid
Description: naproxcinod 375 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod 750 mg bid
Description: naproxcinod 750 mg bid
Study: NCT02420587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 208
Description: Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
Study: NCT01636440

Intervention type: DEVICE
Group type: OTHER
Intervention: Conditioned Pain Modulation
Description: Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation

Intervention type: DEVICE
Group type: OTHER
Intervention: Conditioned Pain Modulation
Description: Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
Study: NCT01293162

Intervention type: DRUG
Intervention: Armolipid Prev
Description: Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
Study: NCT00565318

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benfotiamine
Description: 3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3x 1 film coated tablet daily. Duration: 12 weeks.
Study: NCT00723320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 10mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: atorvastatin 10mg/d

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive lifestyle intervention
Description: aggressive lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aggressive lifestyle intervention
Description: aggressive lifestyle intervention
Study: NCT04308616

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples
Study: NCT02055859

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiosurgery

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiosurgery
Study: NCT02883543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: icotinib
Description: Icotinib is orally administered three times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Icotinib is orally administered three times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy is given by intravenous administration. Three regimens are available in this study.~Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.~Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
Study: NCT00800371

Intervention type: PROCEDURE
Intervention: intra-articular steroid injection
Description: Steroid injection into otherwise noncontrollable arthritis.
Study: NCT04991389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129-Xe
Description: Inhaled contrast for MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 129-Xe
Description: Inhaled contrast for MRI
Study: NCT03909165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Description: For moderate NMB reversal, a single IV bolus of sugammadex (2 mg/kg) will be given after final dose of neuromuscular blocking agent (NMBA; rocuronium or vecuronium) and within 2 minutes of the reappearance of a second twitch (T2) in response to train-of-four (TOF) stimulations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Description: For deep NMB reversal, a single IV bolus of sugammadex (4 mg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of detection of a target of 1 to 2 post-tetanic counts and no response to TOF stimulations (TOF=0).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine + Glycopyrrolate
Description: For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as glycopyrrolate (10 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine + Atropine
Description: For moderate NMB reversal, a single i.v. bolus containing both neostigmine (50 μg/kg; up to 5 mg maximum dose) as well as atropine (20 μg/kg) will be given after final dose of NMBA (rocuronium or vecuronium) and within 2 minutes of the reappearance of T2 in response to TOF stimulations.
Study: NCT00662896

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 250 mg bid
Description: naproxen 250 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen 500 mg bid
Description: naproxen 500 mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen 600 mg tid
Description: ibuprofen 600 mg tid
Study: NCT01661517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and referral to treatment
Study: NCT01728272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: blood concentration of metoprolol
Description: measure blood concentration of metoprolol
Study: NCT00610883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
Description: LSA4 intervention includes three phases: induction, consolidation and maintenance
Study: NCT04637659

Intervention type: PROCEDURE
Intervention: Root Canal Treatment
Description: Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
Study: NCT00744458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment contract
Description: Patients signs in for a agreement - to respect a regular follow-up at the health facility.
Study: NCT04637659

Intervention type: PROCEDURE
Intervention: Root Canal Treatment
Description: Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.

Intervention type: PROCEDURE
Intervention: Root Canal Treatment
Description: Chemo-mechanical preparation will be performed using reciprocating instruments . Irrigation will be carried out with 5.25% NaOCl during instrumentation and a final flush of 17% EDTA followed by 5.25% NaOCl. After drying with paper points, canal obturation will be achieved through continuous condensation wave technique. Obturation with gutta-percha will be performed using Reciproc blue R25 master cones and root canal sealer using the BeeFill 2 in 1 device (VDW, GmbH) with a small heat carrier (#40 tip size and .03 taper) following the manufacturer's instructions. After the down-packing phase, the back-filling will be performed with the same device and manual compaction using endodontic pluggers.
Study: NCT00514007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: OSI-906 administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSI-906
Description: OSI-906 administered orally
Study: NCT04238455

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham serratus anterior plane block
Description: The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus anterior plane block
Description: The serratus anterior plane block will be performed by the anesthesiology team just prior to emergence from general anesthesia.
Study: NCT04188964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
Study: NCT02559076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ten Steps leaflet advice for healthy lifestyle
Description: Ten steps leaflet advice for healthy lifestyle
Study: NCT01093573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midostaurin
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given IV
Study: NCT05328778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
Study: NCT00744458

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment contract
Description: Patients signs in for a agreement - to respect a regular follow-up at the health facility.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment contract
Description: Patients signs in for a agreement - to respect a regular follow-up at the health facility.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracing and recall at home by a community worker
Description: The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Incentive
Description: Incentive by giving free treatment after a 4-month regular follow-up
Study: NCT05328778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Each patient received a single dose administration of sugammadex 2mg/kg according to the ideal body weight (IBW) at reappearance of the second twitch of the train-of-four (TOF).
Study: NCT03136211

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIRA intervention
Description: Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
Study: NCT01950481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Oral LDK378 750 mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Oral LDK378 750 mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Oral LDK378 750 mg once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDK378
Description: Oral LDK378 750 mg once
Study: NCT02260193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
Study: NCT02816710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conbercept
Description: Conbercept is a humanized soluble fusion protein which has a high binding affinity to the Fc region of human immunoglobulin G1 simultaneously. Prior clinical studies have demonstrated that intravitreal conbercept (IVC) inhibits the process of angiogenesis in vivo and in vitro, and has been recognized as a novel effective treatment strategy for neovascularization, providing an alternative treatment option for ophthalmologists.
Study: NCT03415724

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior alveolar nerve block
Description: Inferior alveolar nerve block will be given to patients having irreversible pulpitis in mandibular molars